Phase I study of tilorone, a non-marrow depressing antitumor agent.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects; D004048:Diethylamines / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D004569:Electroencephalography; D005260:Female; D005449:Fluorenes / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011506:Proteins / Q000378:metabolism
D000970:Antineoplastic Agents; D004048:Diethylamines; D005449:Fluorenes; D011506:Proteins